<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533154</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-280515</org_study_id>
    <nct_id>NCT02533154</nct_id>
  </id_info>
  <brief_title>Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients</brief_title>
  <official_title>Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Benzalkonium chloride (BAC) is a preservative, which is a component of more than 70% of&#xD;
      topical ophthalmic drugs. Although BAC is a preservative with an excellent antibacterial&#xD;
      spectrum, it has also been shown to induce toxic effects to the ocular surface. Several&#xD;
      studies have indicated that BAC may also have altering effects on the bacterial flora of the&#xD;
      conjunctiva.&#xD;
&#xD;
      Since dry eye syndrome (DES) is a very common and multifactorial disease of the ocular&#xD;
      surface and the tear fluid resulting in tear film instability, inflammation of the ocular&#xD;
      surface, symptoms of discomfort and visual impairment, there are many different preserved as&#xD;
      well as preservative-free ophthalmic preparations of ocular lubricants for the treatment of&#xD;
      DES. Unpublished data from our department shows differences between artificial tears for the&#xD;
      treatment of DES with and without BAC in bacterial culture.&#xD;
&#xD;
      Therefore, the aim of this study is to investigate the effect of artificial tear eyedrops&#xD;
      with and without BAC on the conjunctival bacterial flora. For this 40 patients with mild or&#xD;
      moderate dry eye syndrome with no use of artificial tears in the 4 weeks preceding the study&#xD;
      will be recruited and treated either with the preservative-free &quot;Prosicca sine&quot; eyedrops or&#xD;
      the BAC containing &quot;Prosicca&quot; eyedrops for one month. Conjunctival samples will be collected&#xD;
      of one eye of each patient before and after the 1-month treatment period to compare the&#xD;
      conjunctival bacterial flora of the two treatment groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of colony forming units (CFU) in bacterial culture of conjunctival swab</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Break Up Time (BUT)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer I test</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSDI© score</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instillation frequency</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>BAC treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-BAC treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prosicca</intervention_name>
    <description>Prosicca eyedrops Dosage: on demand Route of administration: topical</description>
    <arm_group_label>BAC treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prosicca sine</intervention_name>
    <description>Prosicca sine eyedrops Dosage: on demand Route of administration: topical</description>
    <arm_group_label>non-BAC treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bacterial culture</intervention_name>
    <description>bacterial cultures obtained with conjunctival swabs</description>
    <arm_group_label>BAC treatment group</arm_group_label>
    <arm_group_label>non-BAC treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 18 and 75 years.&#xD;
&#xD;
          -  Signed and dated written informed consent.&#xD;
&#xD;
          -  History of dry eye syndrome for at least 3 months&#xD;
&#xD;
          -  Tear Break Up Time (BUT) ≤ 10 seconds or Schirmer I test ≤ 10 mm and ≥ 2mm&#xD;
&#xD;
          -  Normal ophthalmic findings except dry eye syndrome, ametropia &lt; 6 Dpt.&#xD;
&#xD;
          -  Recommended use of topical lubricants, but no administration of topical lubricants 4&#xD;
             weeks preceding the first study day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of ocular disease judged by the investigator as incompatible with&#xD;
             the study.&#xD;
&#xD;
          -  Any other topical ocular treatment than the study medication in the 4 weeks preceding&#xD;
             the first study day and during the treatment period.&#xD;
&#xD;
          -  Wearing of contact lenses.&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day.&#xD;
&#xD;
          -  Participation in a clinical trial in the 3 weeks preceding the first study day.&#xD;
&#xD;
          -  Pregnancy, lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Garhöfer, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>29810</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhofer, MD</last_name>
      <phone>00431 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhoefer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

